Elsa F Mateus
A5068189138- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Spondyloarthritis Studies and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Musculoskeletal Disorders and Rehabilitation
- Peripheral Neuropathies and Disorders
- COVID-19 and healthcare impacts
- Adolescent and Pediatric Healthcare
- Mental Health and Patient Involvement
- Dermatological and COVID-19 studies
- Healthcare Systems and Technology
- Clinical practice guidelines implementation
- Empathy and Medical Education
- Systemic Sclerosis and Related Diseases
- Inflammasome and immune disorders
- Intramuscular injections and effects
- COVID-19 and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- Heparin-Induced Thrombocytopenia and Thrombosis
- COVID-19 diagnosis using AI
- Global Public Health Policies and Epidemiology
- Immunodeficiency and Autoimmune Disorders
Portuguese League Against Epilepsy
2019-2024
European League Against Rheumatism
2019-2024
Universidade Nova de Lisboa
2021-2024
The Geneva Association
2023-2024
Colorado School of Public Health
2023
University of Colorado Anschutz Medical Campus
2023
Benaroya Research Institute
2023
University of California, San Diego
2023
Justus-Liebig-Universität Gießen
2022
Instituto de Salud Musculoesquelética
2022
COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated hospitalisation status disease.Case series of individuals disease from the Global Rheumatology Alliance registry: 24 March 2020 20 April 2020. Multivariable logistic regression used estimate ORs 95% CIs hospitalisation. Age, sex, smoking status, diagnosis, comorbidities medications taken immediately prior infection were analysed.A total 600 cases 40...
To determine factors associated with COVID-19-related death in people rheumatic diseases.
Individuals with inflammatory rheumatic disease require special consideration regard to coronavirus 2019 (COVID-19), caused by the severe acute respiratory syndrome 2 (SARS-CoV-2). Many of these individuals are considered at-risk for serious infections due their immunocompromised state resulting from underlying immune conditions and use targeted immune-modulating therapies such as biologics.1–4 However, some disease-modifying drugs commonly used treat diseases, hydroxychloroquine, being...
To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).We analysed the Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD for RA at clinical onset (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 (IL-6i) tumour necrosis factor (TNFi, reference group). The ordinal severity...
To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).Physician-reported registry I-RMD non-inflammatory RMD (NI-RMDs) patients vaccinated SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, diagnosis, activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) breakthrough infections. Data were analysed descriptively.The study included...
<h3>Aim</h3> To determine characteristics associated with more severe outcomes in a global registry of people systemic lupus erythematosus (SLE) and COVID-19. <h3>Methods</h3> People SLE COVID-19 reported the Global Rheumatology Alliance from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised no oxygenation, (3) any ventilation or oxygenation (4) death. A multivariable logistic regression model constructed assess relationship...
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...
To assess the impact of COVID-19 pandemic on patients with rheumatic and musculoskeletal diseases (RMDs).REUMAVID is a cross-sectional study using an online survey developed by international multidisciplinary patient-led collaboration across seven European countries targeting unselected RMDs. Healthcare access, daily activities, disease activity function, well-being (WHO Five Well-Being Index (WHO-5)), health status, anxiety/depression (Hospital Anxiety Depression Scale (HADS)) access to...
To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic (SRD).An international study was conducted from 2 April to 16 August 2021, using an online survey of 5619 adults SRD for adverse events vaccination, including flares requiring a change treatment. We examined identified priori based on published associations activity SARS-CoV-2 severity, demographics, type, comorbidities, vaccine cessation immunosuppressive...
Objective While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analysed the clinical characteristics of patients with rheumatic disease who developed breakthrough after against SARS-CoV-2. Methods included partially or fully vaccinated SARS-CoV-2 between 5 January and 30 September 2021 were reported to Global Rheumatology Alliance registry. Breakthrough infections defined as occurring ≥14 days completion...
Background Since the publication of 2011 European Alliance Associations for Rheumatology (EULAR) recommendations patient research partner (PRP) involvement in rheumatology research, role PRPs has evolved considerably. Therefore, an update was deemed necessary. Methods In accordance with EULAR Standardised Operational Procedures, a task force comprising 13 researchers, 2 health professionals and 10 convened. The process included online meeting, systematic literature review in-person second...
<h3>Objectives</h3> Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome children, children young people (CYP) overall less prone to severe COVID-19 most experience a mild or asymptomatic course. However, it is unknown if CYP RMDs more likely have COVID-19. This analysis aims describe outcomes among underlying <h3>Methods</h3> Using the European Alliance Associations for...
Objectives To investigate factors associated with severe COVID-19 in people psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Methods Demographic data, clinical characteristics outcome severity of adults PsO, PsA axSpA were obtained from two international physician-reported registries. A three-point ordinal scale was defined: no hospitalisation, hospitalisation (and death) death. ORs estimated using multivariable logistic regression. Results Of 5045 cases, 18.3%...
<h3>Background:</h3> The consequences of the COVID-19 outbreak are unprecedented and have been felt by everyone around world, including people with rheumatic musculoskeletal diseases (RMDs). With development vaccines, future is becoming brighter. Vaccines a key pillar public health proven to prevent many serious diseases. However, vaccination also raises questions, especially for patients inflammatory RMDs and/or treated drugs that influence their immune system. <h3>Objectives:</h3> Our aim...
To determine the association between race/ethnicity and COVID-19 outcomes in individuals with systemic lupus erythematosus (SLE).
Patient global assessment (PGA) is purported to add the patient's perspective in composite measures of RA. However, PGA not standardized and it known whether patients' interpretation measure consistent with its intended purpose. This study aimed explore difficulties experienced by patients RA completing PGA, assess impact a structured explanation improving validity reliability.This was mixed methods study, using interviews, focus groups data. During (convenience sample, n = 33) completed...
Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between and meta-analyses.To develop Points to Consider (PtC) for design, analysis reporting of patients inflammatory arthritis include WP a primary or secondary domain.The EULAR Standardised Operating Procedures were followed. A multidisciplinary taskforce 22 experts including rheumatic diseases, from 10 countries Canada, identified methodologic...
Objectives To investigate factors associated with severe COVID-19 in people idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and outcome severity of adults IIM were obtained from the Global Rheumatology Alliance physician-reported registry. A 3-point ordinal scale was defined: (1) no hospitalisation, (2) hospitalisation (and death) (3) death. ORs estimated using multivariable logistic regression. Sensitivity analyses performed a 4-point scale: oxygen...
Background There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic musculoskeletal diseases (RMDs). Current guidance based from adults RMDs or CYP without RMDs. Objectives To describe the SARS-COV-2 adolescents inflammatory juvenile idiopathic arthritis (JIA). Methods We described patient characteristics, flares adverse events (AEs) adolescent cases under 18 adult aged above JIA submitted to European Alliance Associations for Rheumatology...